Conavi Medical extends Japan Lifeline debt to 2032 at 10% interest
The senior secured facilities previously matured in April 2027; interest generally remains deferred until maturity.

An April 2027 debt maturity has moved to April 2032 after Conavi Medical Corp. CVECNVI OTCMKTSCNVIF announced a five-year extension on Wednesday. The annual interest rate rises to 10 per cent from 6.5 per cent.
The Nov. 18 announcement identifies the lender as Tokyo-listed Japan Lifeline Co., Ltd. TYO7575. Conavi said it generally does not have to pay interest until maturity under the existing terms.
Conavi is a small Toronto medical-device maker beginning U.S. commercialization of equipment that lets cardiologists view coronary arteries from inside the vessel.
Its TSX Venture shares closed at C$0.13 on Nov. 17 at 4:00 p.m. EST CVECNVI, before the extension announcement. Management's stated priorities are additional hospital placements, physician adoption and further clinical evidence.
Higher Interest Accompanies The Longer Term
The higher rate increases the cost of carrying the borrowing even while cash interest is generally deferred. The announcement describes an extension of existing senior secured facilities and does not announce new borrowing or disclose detailed covenants, fees or other amendment conditions.
Conavi reported C$0.9 million in cash at June 30 in its Aug. 27 quarterly update. It subsequently closed a C$10 million public equity offering on Aug. 12 to support its U.S. market release, working capital and general corporate purposes. The extension announcement does not update cash or provide a cash runway.
The quarter ended June 30 brought a net loss of C$6.3 million, versus C$3.6 million in the corresponding prior-year quarter. Research and development spending reached C$4.4 million as Conavi worked on its next-generation system and preparations for production.
Licensing and research-services revenue was C$0.1 million for the quarter ended June 30. Conavi attributed the decline in nine-month revenue to milestone revenue under a technology-transfer and licensing agreement that did not recur in the current fiscal year.
Read more: Cerenome reports US$0.7M CNSide revenue with trial data due in 2027
"Our focus is on expanding hospital placements, supporting physician adoption and generating additional clinical evidence demonstrating the value of hybrid imaging in coronary interventions," Conavi chief executive Thomas Looby said in the release.
Hospital Adoption Follows U.S. Clearance
Conavi received the next-generation system's FDA 510(k) clearance on April 20, according to its quarterly update. Clearance allowed it to proceed with a targeted U.S. market release, with manufacturing readiness and initial inventory among its preparatory activities.
OCTIV acquires intravascular ultrasound and optical coherence tomography images through one catheter. Conavi says the aligned images give physicians complementary information when making treatment decisions during coronary procedures.
The company's Nov. 2 commercial update reported its first U.S. placement and patient procedures with the FDA-cleared system. The Nov. 18 release provides no numerical target or timetable for additional hospital placements.
Read more: Medtronic gains FDA clearance for Hugo robot in general surgery
The coronary-imaging peer set includes Boston Scientific Corporation NYSEBSX, whose AVVIGO+ product page describes a platform combining intravascular ultrasound with physiological measurements. OCTIV's combination instead pairs ultrasound with optical coherence tomography, making the imaging approach central to Conavi's hospital-adoption plans.
In the wider device sector, the iShares U.S. Medical Devices ETF NYSEARCAIHI was quoted at US$58.02 as of Nov. 13 at 8:00 p.m. EST. The fund price predates Conavi's extension announcement.
Conavi says further regulatory filings will detail the amendment, but the Nov. 18 release gives no filing date or dated hospital-placement milestone. The facilities now mature in April 2032, when repayment comes due under the extended timetable.
Adrian Kessler






